Nimotop S (Nimodipine)

Nimodipine, the active ingredient in Nimotop S, is a calcium channel blocker presented as an injectable solution for intravenous use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage, helping to reduce the risk of delayed ischemic neurological deficits in affected patients.

GNH USA supplies Nimotop S as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Nimodipine acts on the cerebrovascular system to manage conditions associated with vessel constriction.

Prevention of cerebral vasospasm after subarachnoid hemorrhage: reduces the incidence of delayed ischemic neurological deficits. Adjunct in acute cerebral vasospasm management: supports restoration of cerebral blood flow.

Nimodipine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypotension: mild to moderate drop in blood pressure. - Headache: transient cranial discomfort. - Nausea: occasional gastrointestinal upset. - Flushing: warmth and redness of the skin. - Dizziness: sensation of light‑headedness. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure reduction requiring intervention. - Myocardial infarction: rare cardiac ischemic events. - Allergic reaction: rash, itching, or anaphylaxis. - Hepatic dysfunction: abnormal liver enzyme elevations. - Thrombocytopenia: low platelet count. - Seizures: infrequent neurologic events.

Before initiating therapy, clinicians should consider several safety measures.

Monitor blood pressure: watch for excessive hypotension during infusion. Avoid rapid infusion: administer over the recommended time to reduce cardiovascular stress. Use with caution in hepatic impairment: adjust dosing if liver function is compromised. Assess for drug interactions: review concomitant medications that affect vascular tone. Do not use in patients with known hypersensitivity to nimodipine or related compounds. Store at ambient temperature: keep in original packaging, protect from moisture and light.

Nimodipine can interact with other drugs, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent use with other potent vasodilators: may cause severe hypotension. - Combination with beta‑blockers: risk of additive blood pressure lowering. - Co‑administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increases plasma concentrations.

Moderate Interactions (Monitor Closely): - Use with other calcium channel blockers: may enhance vasodilatory effects. - Concomitant diuretics: can affect electrolyte balance and blood pressure. - Interaction with antiplatelet agents: may increase bleeding tendency.